Genscript Biotech Corporation (GNNSF) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Nanjing, 中国. 現CEOは Weihui Shao.
GNNSF を有する IPO日 2017-09-28, 5,568 名の正社員, に上場 Other OTC, 時価総額 $3.1B.
Genscript Biotech Corporation is a global life science company founded in 2002 and headquartered in Nanjing, China, serving customers across North America, Europe, Asia Pacific, and internationally. The company operates through four primary segments: Life Science Services and Products, which provides gene synthesis, protein engineering, antibody development, and molecular diagnostics tools for research and drug discovery; Biologics Development Services, offering antibody drug development, gene therapy, and cell therapy development for pharmaceutical and biotech clients; Industrial Synthetic Biology Products, which manufactures microbial strains and industrial enzymes for food, pharmaceutical, and chemical industries; and Cell Therapy, focusing on chimeric antigen receptor T-cell therapies for cancer treatment. Through these integrated business segments, Genscript delivers comprehensive research products and development services that support basic biology studies, pharmaceutical discovery, disease diagnostics, and therapeutic development.
